Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 8;10(6):e004512. doi: 10.1136/jitc-2022-004512

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

The combination therapy induces clonotype modulation in CR patients, represented by the top clonotype profiles. (A–C) Tracking the relative abundance (estimated from DeepTCR) of top 10 most abundant clonotypes in three patients in CR: (A) MCC014(A), (B) MCC069, and (C) MCC055. (D) The density distribution of TCR aa sequences under positive and negative selection after the combination therapy. The log2FC (fold-change) is calculated by log2 transformation of clonotype (relative) frequency fold-change between EOT and pretreatment time points. CR, complete response; EOT, end of treatment; TCR, T cell receptor.